Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells.
Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells.
复制标题
DOI：
10.3389/fimmu.2017.00961
复制
发表时间：
2017
影响因子：
7.3
通讯作者：
Dong H
中科院分区：
文献类型：
--
作者：
Gibbons Johnson RM;Dong H
程序性死亡-1（PD-1）及其配体PD-L1（B7-H1）信号传导途径一直是肿瘤免疫学和肿瘤学领域的焦点，最近FDA批准了抗PD-1抗体派姆单抗和纳武单抗以及抗PD-L1抗体度伐鲁单抗、阿特珠单抗和阿维鲁单抗。这些疗法在本文中被称为PD-L1/PD-1检查点阻断疗法，旨在阻断肿瘤细胞表达的PD-L1与肿瘤浸润性CD 8 + T细胞表达的PD-1之间的相互作用，从而增强抗肿瘤CD 8 + T细胞应答和肿瘤消退。肿瘤细胞表达的PD-L1对抗肿瘤CD 8 + T细胞应答的影响已得到充分表征，但免疫细胞表达的PD-L1对抗肿瘤CD 8 + T细胞应答的影响尚未得到充分确定。尽管肿瘤细胞的PD-L1表达已被用作选择PD-L1/PD-1检查点阻断治疗患者的生物标志物，但肿瘤细胞缺乏PD-L1表达的患者通常对PD-L1/PD-1检查点阻断治疗有积极反应。这表明由非恶性细胞表达的PD-L1也可能有助于抗肿瘤免疫。在这里，我们回顾了免疫细胞表达的PD-L1在CD 8 + T细胞引发、收缩和分化为记忆群体的背景下的功能，以及肿瘤细胞表达的PD-L1在调节抗肿瘤CD 8 + T细胞应答中的作用。
The programmed death-1 (PD-1) and its ligand PD-L1 (B7-H1) signaling pathway has been the focus of much enthusiasm in the fields of tumor immunology and oncology with recent FDA approval of the anti-PD-1 antibodies pembrolizumab and nivolumab and the anti-PD-L1 antibodies durvalumab, atezolimuab, and avelumab. These therapies, referred to here as PD-L1/PD-1 checkpoint blockade therapies, are designed to block the interaction between PD-L1, expressed by tumor cells, and PD-1, expressed by tumor-infiltrating CD8+ T cells, leading to enhanced antitumor CD8+ T cell responses and tumor regression. The influence of PD-L1 expressed by tumor cells on antitumor CD8+ T cell responses is well characterized, but the impact of PD-L1 expressed by immune cells has not been well defined for antitumor CD8+ T cell responses. Although PD-L1 expression by tumor cells has been used as a biomarker in selection of patients for PD-L1/PD-1 checkpoint blockade therapies, patients whose tumor cells lack PD-L1 expression often respond positively to PD-L1/PD-1 checkpoint blockade therapies. This suggests that PD-L1 expressed by non-malignant cells may also contribute to antitumor immunity. Here, we review the functions of PD-L1 expressed by immune cells in the context of CD8+ T cell priming, contraction, and differentiation into memory populations, as well as the role of PD-L1 expressed by tumor cells in regulating antitumor CD8+ T cell responses.
登录
查看更多内容
杜瓦卢马布（Durvalumab）和非小细胞肺癌中的tremelimumab的安全性和抗肿瘤活性：多中心1B研究。
DOI：
10.1016/s1470-2045(15)00544-6
发表时间：
2016-03
期刊：
The Lancet. Oncology
影响因子：
--
作者：
Antonia S;Goldberg SB;Balmanoukian A;Chaft JE;Sanborn RE;Gupta A;Narwal R;Steele K;Gu Y;Karakunnel JJ;Rizvi NA
通讯作者：
Rizvi NA
影响因子：
4.4
作者：
Chemnitz, JM;Parry, RV;Riley, JL
通讯作者：
Riley, JL
影响因子：
15.9
作者：
Baitsch, Lukas;Baumgaertner, Petra;Speiser, Daniel E.
通讯作者：
Speiser, Daniel E.
影响因子：
11.2
作者：
Blank, C;Brown, I;Gajewski, TF
通讯作者：
Gajewski, TF
影响因子：
5.4
作者：
Cham, Candace M.;Driessens, Gregory;O'Keefe, James P.;Gajewski, Thomas F.
通讯作者：
Gajewski, Thomas F.